On March 21, 2024 Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, reported its upcoming presentations at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting taking place from April 5-10, 2024, in San Diego, California (Press release, Carisma Therapeutics, MAR 21, 2024, View Source [SID1234641363]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation will showcase preclinical data illustrating the advancements made with Carisma’s proprietary Engineered Microenvironment Converters (EM-C) platform. Furthermore, Michael Klichinsky, PharmD, PhD, Co-Founder, and Chief Scientific Officer at Carisma, will present "Engineering Macrophages for Cancer Immunotherapy: CARs and Beyond" during the Major Symposium session titled "Engineering Strategies Based on NK, gd T Cells and Their Receptors, and Macrophages," scheduled for Wednesday, April 10, 2024, from 10:15 AM to 11:45 AM PT.
Details on the poster presentation at AACR (Free AACR Whitepaper) 2024 are below:
Poster Title: Macrophages Expressing Synthetic Cytokine Receptors Reverse IL10-Mediated Immunosuppression within Solid Tumors and Promote Adaptive Immunity
Session Title: Adoptive Cell Therapies 4
Abstract Number: 5249
Session Date & Time: Tuesday, April 9, 2024, 1:30 PM – 5:00 PM PT